Ultragenyx Pharmaceutical (NASDAQ:RARE) Earns “Overweight” Rating from Cantor Fitzgerald

Ultragenyx Pharmaceutical (NASDAQ:RARE)‘s stock had its “overweight” rating reissued by equities research analysts at Cantor Fitzgerald in a research note issued on Wednesday,Benzinga reports. They currently have a $118.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 163.10% from the stock’s current price. Cantor Fitzgerald also issued estimates for Ultragenyx Pharmaceutical’s FY2025 earnings at ($4.44) EPS.

Other equities research analysts also recently issued research reports about the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Canaccord Genuity Group reissued a “buy” rating and set a $121.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. JPMorgan Chase & Co. dropped their price objective on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a report on Thursday, November 21st. TD Cowen increased their target price on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, Wells Fargo & Company boosted their price target on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research note on Friday, December 20th. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $92.43.

Ultragenyx Pharmaceutical Price Performance

NASDAQ RARE opened at $44.85 on Wednesday. Ultragenyx Pharmaceutical has a 12 month low of $37.02 and a 12 month high of $60.37. The stock has a market capitalization of $4.14 billion, a P/E ratio of -6.93 and a beta of 0.58. The firm’s 50-day moving average is $44.63 and its two-hundred day moving average is $49.59.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.45) by $0.05. The firm had revenue of $139.49 million during the quarter, compared to analysts’ expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The firm’s quarterly revenue was up 42.3% on a year-over-year basis. During the same quarter last year, the company posted ($2.23) EPS. As a group, analysts anticipate that Ultragenyx Pharmaceutical will post -6.14 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Emil D. Kakkis sold 11,727 shares of the company’s stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $42.23, for a total value of $495,231.21. Following the completion of the sale, the chief executive officer now directly owns 2,183,985 shares of the company’s stock, valued at $92,229,686.55. This represents a 0.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 5.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. True Wealth Design LLC acquired a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at $43,000. Values First Advisors Inc. acquired a new position in Ultragenyx Pharmaceutical in the third quarter valued at $56,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at about $83,000. Nomura Asset Management Co. Ltd. purchased a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at about $93,000. Finally, Capital Performance Advisors LLP acquired a new stake in shares of Ultragenyx Pharmaceutical during the third quarter worth about $107,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.